Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized open-label study to compare between in-vitro
fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes of the two regimen of
Cetrotide® (Cetrorelix acetate) which are 0.25 milligram (mg) used from Day 1 or Day 7 of the
menstrual cycle (Day 0 or Day 6 of stimulation) in polycystic ovarian (PCO) women in assisted
reproductive technology (ART).